PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

NCT04041128 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Breast Cancer

Interventions

DRUG: Lynparza

Sponsor

University of Texas Southwestern Medical Center